Introduction. Treatment-Resistant Schizophrenia and Beyond: Current Concepts and Future Prospects.

View This PDF

NB: This article is only available as a PDF.

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The publication of the U.S. Clozaril Multicenter Trial more than a decade ago led to the worldwide use of clozapine (Clozaril, Leponex) for treatment-resistant schizophrenia.1 Despite the subsequent introduction of other atypical antipsychotics, clozapine remains the “gold standard” for treatment of this patient population, with superior efficacy compared with conventional antipsychotics. Indeed, it is the only drug with proven efficacy in treatmentresistant schizophrenia.​

J Clin Psychiatry 1999;60(suppl 12):3-3